C. Pargellis

发表

A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket

L. Tong, S. Pav, D. White, 1997, Nature Structural Biology.

Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site

L. Tong, S. Pav, C. Pargellis, 2002, Nature Structural Biology.

The discovery of carboline analogs as potent MAPKAP-K2 inhibitors.

Michel Emmanuel, Mohammed A Kashem, Lori Patnaude, 2007, Bioorganic & medicinal chemistry letters.

Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.

J. Madwed, L. Tong, S. Pav, 2002, Journal of medicinal chemistry.

Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site

Liang Tong, Eugene R. Hickey, John W. Regan, 2002 .

Suicide recombination substrates yield covalent lambda integrase-DNA complexes and lead to identification of the active site tyrosine.

C. Pargellis, L. M. de Vargas, S. Nunes-Düby, 1988, The Journal of biological chemistry.

Discovery and characterization of the N-phenyl-N'-naphthylurea class of p38 kinase inhibitors.

K. Qian, J. Madwed, C. Pargellis, 2009, Bioorganic & medicinal chemistry letters.

Catalysis and Function of the p38α·MK2a Signaling Complex

C. Pargellis, B. Werneburg, S. Lukas, 2004 .

The kinetics of binding to p38MAP kinase by analogues of BIRB 796.

C. Pargellis, P. Cirillo, T. Gilmore, 2003, Bioorganic & medicinal chemistry letters.

Trichodiene biosynthesis and the stereochemistry of the enzymatic cyclization of farnesyl pyrophosphate

D. Cane, C. Pargellis, H. Ha, 1985 .

Partial purification and characterization of pentalenene synthase.

D. Cane, C. Pargellis, 1987, Archives of biochemistry and biophysics.

Crystallization and preliminary crystallographic analysis of recombinant human p 38 MAP kinase

L. Tong, D. White, C. Cywin, 2002 .

Characterization of the binding site for nevirapine (BI-RG-587), a nonnucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase.

S. Rogers, C. Pargellis, R. Ingraham, 1991, The Journal of biological chemistry.

Effect of deoxycoformycin and Val-boroPro on the associated catalytic activities of lymphocyte CD26 and ecto-adenosine deaminase.

P. Reilly, J. Woska, D. Jeanfavre, 1996, Biochemical pharmacology.

Identification and Characterization of the N-Ethylmaleimide-sensitive Site in λ-Integrase*

C. Pargellis, R. Tirumalai, A. Landy, 1996, The Journal of Biological Chemistry.

Time-resolved ligand exchange reactions: kinetic models for competitive inhibitors with recombinant human renin.

D. Lamarre, C. Pargellis, G. Jung, 1995, Journal of medicinal chemistry.

Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease

D. Lamarre, C. Yoakim, P. Anderson, 1997, Antimicrobial agents and chemotherapy.

Structure-activity relationships of the p38alpha MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl]urea (BIRB 796).

J. Madwed, C. Pargellis, P. Cirillo, 2003, Journal of medicinal chemistry.

Synthesis and SAR studies of indole-based MK2 inhibitors.

M. Hao, C. Pargellis, B. Werneburg, 2008, Bioorganic & medicinal chemistry letters.

New modifications to the area of pyrazole-naphthyl urea based p38 MAP kinase inhibitors that bind to the adenine/ATP site.

K. Qian, J. Madwed, C. Pargellis, 2007, Bioorganic & medicinal chemistry letters.

Inhibition of dipeptidyl peptidase IV (CD26) by peptide boronic acid dipeptides.

S. J. Campbell, S. Pav, C. Pargellis, 1997, Journal of enzyme inhibition.

Determination of kinetic rate constants for the binding of inhibitors to HIV-1 protease and for the association and dissociation of active homodimer.

S. Pav, D. Lamarre, P. Anderson, 1994, Biochemistry.

Crystal structure of human immunodeficiency virus (HIV) type 2 protease in complex with a reduced amide inhibitor and comparison with HIV-1 protease structures.

L. Tong, S. Pav, D. Lamarre, 1993, Proceedings of the National Academy of Sciences of the United States of America.

BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen‐activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth

Hiroshi Yasui, P. Richardson, C. Pargellis, 2007, British journal of haematology.

Crystallization and preliminary crystallographic analysis of recombinant human p38 MAP kinase

L. Tong, S. Pav, D. White, 1997, Protein science : a publication of the Protein Society.

Molecular basis of MAPK-activated protein kinase 2:p38 assembly

Bennett T. Farmer, B. Farmer, C. Pargellis, 2007, Proceedings of the National Academy of Sciences.

Procede de purification de proteines

C. Pargellis, M. Staples, 1990 .

Inhibition of pro-inflammatory cytokine production by the dual p38/JNK2 inhibitor BIRB796 correlates with the inhibition of p38 signaling.

J. Woska, C. Pargellis, G. W. Peet, 2009, Biochemical pharmacology.

Inhibitors of p38 mitogen-activated protein kinase for the treatment of rheumatoid arthritis.

C. Pargellis, J. Regan, 2003, Current opinion in investigational drugs.

Autonomous DNA binding domains of λ integrase recognize two different sequence families

C. Pargellis, A. Landy, N. Hasan, 1988, Cell.

Discovery and optimization of p38 inhibitors via computer-assisted drug design.

Angela Berry, Jinhua J. Song, Ming-Hong Hao, 2007, Journal of medicinal chemistry.

Thermal denaturation: a method to rank slow binding, high-affinity P38alpha MAP kinase inhibitors.

C. Pargellis, J. Regan, G. W. Peet, 2003, Journal of medicinal chemistry.

Catalysis and function of the p38 alpha.MK2a signaling complex.

C. Pargellis, B. Werneburg, S. Lukas, 2004, Biochemistry.

Discovery and characterization of a substrate selective p38alpha inhibitor.

C. Pargellis, B. Werneburg, S. Lukas, 2004, Biochemistry.

Structure-based design and subsequent optimization of 2-tolyl-(1,2,3-triazol-1-yl-4-carboxamide) inhibitors of p38 MAP kinase.

M. Hao, K. Qian, C. Pargellis, 2008, Bioorganic & medicinal chemistry letters.

The non-diaryl heterocycle classes of p38 MAP kinase inhibitors.

John Regan, C. Pargellis, P. Cirillo, 2002, Current topics in medicinal chemistry.

Microtube batch protein crystallization: Applications to human immunodeficiency virus type 2 (HIV‐2) protease and human renin

L. Tong, S. Pav, D. Lamarre, 1994, Proteins.